Eli Lilly Weight Loss Drug: 29% Weight Loss Results
“`html
Eli Lilly’s orforglipron Shows Promising Weight Loss Results in Trials
Table of Contents
New data reveals Eli Lilly’s oral weight-loss drug, orforglipron, demonstrated meaningful weight reduction in clinical trials, potentially offering a new option for individuals struggling wiht obesity and related conditions. the drug is expected to be available in 2024.
Key Findings from Orforglipron Trials
Eli Lilly announced on Thursday, December 7, 2023, that its experimental oral drug, orforglipron, led to weight loss of up to 29% in clinical trials Financial Times. The trials involved individuals with obesity or who were overweight and had at least one weight-related health condition. Patients taking the highest dose of orforglipron experienced the most significant weight reduction.
The drug works by activating the GLP-1 receptor, similar to popular injectable weight-loss medications like Wegovy and Mounjaro, both also produced by Eli Lilly Reuters. However, orforglipron is administered as a pill, offering a potentially more convenient option for patients.
Side Effects and regulatory Review
The side effects observed in the orforglipron trials were reported to be similar to those associated with Eli Lilly’s injectable weight-loss drugs Financial times. These commonly include nausea, diarrhea, and vomiting. Approximately 10.5% of patients discontinued treatment due to adverse effects.
The U.S. Food and Drug administration (FDA) has indicated it will prioritize the review of orforglipron, and the drug is anticipated to receive approval and become available for sale in 2024 Reuters. This expedited review process underscores the significant unmet medical need for effective obesity treatments.
Drug Pricing and Access
in November 2023, eli Lilly announced a drug pricing agreement with the Trump administration, aiming to lower the cost of its weight-loss drugs in exchange for broader access through U.S. federal health programs financial Times. details of this agreement are still emerging, but it signals a potential shift in pharmaceutical pricing strategies.